<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id>
      <journal-title-group>
        <journal-title>Orphanet Journal of Rare Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1750-1172</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">25497359</article-id>
      <article-id pub-id-type="pmc">4266221</article-id>
      <article-id pub-id-type="publisher-id">208</article-id>
      <article-id pub-id-type="doi">10.1186/s13023-014-0208-3</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Letter to the Editor</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Treatment of motor and behavioural symptoms in three Lesch-Nyhan patients with intrathecal baclofen</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Pozzi</surname>
            <given-names>Marco</given-names>
          </name>
          <address>
            <email>marco.pozzi@bp.lnf.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Piccinini</surname>
            <given-names>Luigi</given-names>
          </name>
          <address>
            <email>luigi.piccinini@unimi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gallo</surname>
            <given-names>Maurizio</given-names>
          </name>
          <address>
            <email>maurizio.gallo@unimi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Motta</surname>
            <given-names>Francesco</given-names>
          </name>
          <address>
            <email>f.motta@icp.mi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Radice</surname>
            <given-names>Sonia</given-names>
          </name>
          <address>
            <email>sonia.radice@unimi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Clementi</surname>
            <given-names>Emilio</given-names>
          </name>
          <address>
            <email>emilio.clementi@unimi.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <aff id="Aff1"><label/>Scientific Institute IRCCS Eugenio Medea, 23842 Bosisio Parini, Lecco, Italy </aff>
        <aff id="Aff2"><label/>Scuola di Specializzazione in Medicina Fisica e Riabilitativa, Universit&#xE0; di Milano, 20122 Milan, Italy </aff>
        <aff id="Aff3"><label/>Paediatric Orthopedics and Traumatology, Children&#x2019;s Hospital V. Buzzi, 20126 Milan, Italy </aff>
        <aff id="Aff4"><label/>Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences L. Sacco, &#x201C;Luigi Sacco&#x201D; University Hospital, Universit&#xE0; di Milano, 20157 Milan, Italy </aff>
        <aff id="Aff5"><label/>Unit of Clinical Pharmacology, CNR Institute of Neuroscience, Department of Biomedical and Clinical Sciences L. Sacco, &#x201C;Luigi Sacco&#x201D; University Hospital, Universit&#xE0; di Milano, Via GB Grassi 74, 20157 Milan, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>12</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>12</day>
        <month>12</month>
        <year>2014</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2014</year>
      </pub-date>
      <volume>9</volume>
      <elocation-id>208</elocation-id>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>10</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>3</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Pozzi et al.; licensee BioMed Central Ltd. 2014</copyright-statement>
        <license license-type="open-access">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p>Current therapies for the Lesch-Nyhan Syndrome (OMIM: 300322) are off-label and experimental, often leading to inconsistent outcomes. We here report the effects of an intrathecal baclofen therapy, carried out at the Scientific Institute Eugenio Medea (Lecco, Italy), on three patients who no longer received benefit from previous therapies. This treatment, as expected, ameliorated the motor symptoms and, unexpectedly, it also improved behavioural components. This result may involve a functional interaction between baclofen and dopamine, complemented by an anxiolytic effect. Our observations provide the rationale for the use of intrathecal baclofen administration in the therapy of the Lesch-Nyhan Syndrome.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Lesch-Nyhan syndrome</kwd>
        <kwd>Baclofen</kwd>
        <kwd>Dystonia</kwd>
        <kwd>Self-injurious behaviour</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2014</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Letter to the editor</title>
      <sec id="Sec2">
        <title>Introduction</title>
        <p>The Lesch-Nyhan Syndrome [<xref ref-type="bibr" rid="CR1">1</xref>] (LN) (OMIM: 300322) involves dystonia, ballism, and self-injurious and aggressive behaviours. Although LN is severely disabling, no therapeutic standard can yet be indicated and treatment proceeds on the basis of isolated observations. Many therapies for LN, both pharmacological (antispastic drugs, antipsychotics, anti-parkinsonian drugs, dietary supplements) and cellular (enzyme replacement and stem cell therapies), are currently experimented, with inconsistent results [<xref ref-type="bibr" rid="CR2">2</xref>]. We report on three patients with a genetic diagnosis of classical LN, who were referred to the Scientific Institute Eugenio Medea (Lecco, Italy) for rehabilitation. They were treated with intrathecal baclofen (ITB) and showed an improvement regarding both dystonia and pathological behaviours.</p>
      </sec>
    </sec>
    <sec id="Sec3" sec-type="methods">
      <title>Patients and methods</title>
      <p>Patient 1 was 19&#xA0;years old at referral. During motor development, he never achieved head control, did not crawl or walk; instead, he developed bilateral clubfoot and phasic extensor hypertonia of the upper limbs, with dystonia and ballism. His pathological behaviour involved very severe self-injury and involuntary aggression, by punching and biting. The patient constantly wore whole-body restraints in order to contain these exacerbations. Patient 2 was referred at 39&#xA0;years of age. He never achieved head control, but crawled and walked until 9, when severe dystonia and ballism of the limbs began. He displayed severe finger biting and required permanent finger protection. Patient 3 was 20&#xA0;years old at referral. He never achieved head control, crawled scantly and never walked. He developed strong retropulsive reactions, with dystonia involving neck and limbs, and ballism of the arms. By punching, he injured himself and attacked others. Patients were weaned off their previous therapies (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) and subsequently implanted with the intrathecal drug delivery device Synchromed II - 20&#xA0;ml (Medtronic, Minneapolis, MN, USA). Individual ITB dosages were up titrated to achieve a satisfactory effect on dystonia.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>Patients&#x2019; previous pharmacological therapies</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Patient</bold>
</th><th colspan="3">
<bold>Remote therapeutic history</bold>
</th><th colspan="3">
<bold>Previous therapy before ITB placement</bold>
</th></tr></thead><tbody><tr valign="top"><td valign="middle" rowspan="3">
<bold>1</bold>
</td><td valign="middle" rowspan="3">Trihexyphenidyl</td><td valign="middle" rowspan="3">4&#xA0;mg x3/day</td><td valign="middle" rowspan="3">Started in 2006<break/>Discontinued in 2010</td><td valign="middle" rowspan="3">S-adenosyl methionine</td><td rowspan="3">400&#xA0;mg x4/day</td><td>Started in 2000</td></tr><tr valign="top"><td>Initial efficacy, progressively lost</td></tr><tr valign="top"><td>Discontinued 24/04/2013</td></tr><tr valign="top"><td valign="middle" rowspan="12">
<bold>2</bold>
</td><td valign="middle" rowspan="12">Risperidone</td><td valign="middle" rowspan="12">6&#xA0;mg /day</td><td valign="middle" rowspan="12">Started in 1998<break/>Discontinued in 2011</td><td valign="middle" rowspan="3">Levetiracetam</td><td rowspan="3">250&#xA0;mg x3/day</td><td>Started in 2002</td></tr><tr valign="top"><td>No efficacy</td></tr><tr valign="top"><td>Weaned from 03/01/2014, discontinued 20/02/2014</td></tr><tr valign="top"><td valign="middle" rowspan="3">Clonazepam</td><td rowspan="3">1&#xA0;mg /day</td><td>Started in 2002</td></tr><tr valign="top"><td>Partial efficacy on spasticity</td></tr><tr valign="top"><td>Weaned from 12/02/2014, discontinued 21/02/2014</td></tr><tr valign="top"><td valign="middle" rowspan="3">Sertraline</td><td rowspan="3">50&#xA0;mg /day</td><td>Started in 2002</td></tr><tr valign="top"><td>Scarce efficacy</td></tr><tr valign="top"><td>Weaned from 08/02/2014, discontinued 22/02/2014</td></tr><tr valign="top"><td valign="middle" rowspan="3">Zopiclone</td><td rowspan="3">7.5&#xA0;mg /day</td><td>Started in 2002</td></tr><tr valign="top"><td>Good efficacy on sleep improvement</td></tr><tr valign="top"><td>Weaned from 12/02/2014, discontinued 21/02/2014</td></tr><tr valign="top"><td valign="middle" rowspan="4">
<bold>3</bold>
</td><td valign="middle" rowspan="4">Enzyme replacement therapy</td><td valign="middle" rowspan="3">Intrathecal infusion of leukocytes (2/month)</td><td valign="middle" rowspan="3">Started in 1996<break/>Discontinued in 2010</td><td valign="middle" rowspan="4">Gabapentin</td><td rowspan="4">400&#xA0;mg x4/day</td><td>Started in May, 2013</td></tr><tr valign="top"><td>No efficacy</td></tr><tr valign="top"><td rowspan="2">Weaned from 23/01/2014, discontinued 15/03/2014</td></tr><tr valign="top"><td valign="middle">Intrathecal infusion of mesenchymal stem cells</td><td valign="middle">Single administration in 2012</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec4" sec-type="results">
      <title>Results</title>
      <p>Dystonia was controlled with ITB dosages of 270 to 550&#xA0;&#x3BC;g per day. ITB improved the quality of sleep for all patients, as expected. This happened in the absence of serious adverse reactions; patient 3 only experienced mild drowsiness. In addition, within three days after reaching the stable ITB dosage, ballism was abolished and aggression and self-injurious behaviours ceased, thus allowing the removal of protective restraints (details in Tables&#xA0;<xref rid="Tab2" ref-type="table">2</xref> and <xref rid="Tab3" ref-type="table">3</xref>). The beneficial effects of ITB therapy at unchanged dosages persisted throughout the follow up period (5 to 16&#xA0;months).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Patients&#x2019; symptoms before and after treatment with intrathecal baclofen</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th colspan="2">
<bold>Patient</bold>
</th><th>
<bold>1</bold>
</th><th>
<bold>2</bold>
</th><th>
<bold>3</bold>
</th></tr></thead><tbody><tr valign="top"><td rowspan="11">
<bold>Before ITB</bold>
</td><td>
<bold>Dystonia:</bold>
</td><td rowspan="2">22</td><td rowspan="2">23</td><td rowspan="2">38</td></tr><tr valign="top"><td>
<bold>UDRS total</bold>
<sup><bold>a</bold></sup>
</td></tr><tr valign="top"><td>
<bold>Aggression</bold>
</td><td>Yes</td><td>No</td><td>Yes</td></tr><tr valign="top"><td>
<bold>Self-injury</bold>
<sup><bold>b</bold></sup>
<bold>:</bold>
</td><td/><td/><td/></tr><tr valign="top"><td>
<bold>Mouth/lip biting</bold>
</td><td>2-3</td><td>2</td><td>1-2</td></tr><tr valign="top"><td>
<bold>Finger biting</bold>
</td><td>10</td><td>20</td><td>3-4</td></tr><tr valign="top"><td>
<bold>Punching</bold>
</td><td>10</td><td>0</td><td>2-3</td></tr><tr valign="top"><td>
<bold>Restraint</bold>
</td><td>Permanent whole body restraint</td><td>Permanent finger protection</td><td>None</td></tr><tr valign="top"><td>
<bold>Sleep</bold>
<sup><bold>c</bold></sup>
<bold>:</bold>
</td><td/><td/><td/></tr><tr valign="top"><td>
<bold>Awakenings</bold>
</td><td>7-8</td><td>5-6</td><td>5-6</td></tr><tr valign="top"><td>
<bold>Sleep hours</bold>
</td><td>2</td><td>4</td><td>4</td></tr><tr valign="top"><td colspan="2">
<bold>Date of ITB implantation and age (years)</bold>
</td><td>29/04/2013 &#x2013; 19</td><td>28/02/2014 &#x2013; 39</td><td>19/03/2014 &#x2013; 20</td></tr><tr valign="top"><td colspan="2">
<bold>ITB dosage and follow-up duration (months)</bold>
</td><td>380&#xA0;&#x3BC;g /day &#x2013; 16</td><td>270&#xA0;&#x3BC;g /day &#x2013; 6</td><td>550&#xA0;&#x3BC;g /day &#x2013; 5</td></tr><tr valign="top"><td rowspan="12">
<bold>After ITB</bold>
</td><td>
<bold>Dystonia:</bold>
</td><td rowspan="2">5</td><td rowspan="2">6.5</td><td rowspan="2">11</td></tr><tr valign="top"><td>
<bold>UDRS total</bold>
<sup><bold>a</bold></sup>
</td></tr><tr valign="top"><td>
<bold>Aggression</bold>
</td><td>No</td><td>No</td><td>No</td></tr><tr valign="top"><td>
<bold>Self-injury</bold>
<sup><bold>b</bold></sup>
<bold>:</bold>
</td><td/><td/><td/></tr><tr valign="top"><td>
<bold>Mouth/lip biting</bold>
</td><td>0-1</td><td>0</td><td>0</td></tr><tr valign="top"><td>
<bold>Finger biting</bold>
</td><td>3</td><td>5</td><td>0</td></tr><tr valign="top"><td>
<bold>Punching</bold>
</td><td>0</td><td>0</td><td>0</td></tr><tr valign="top"><td>
<bold>Restraint</bold>
</td><td>Occasional, right arm</td><td>None</td><td>None</td></tr><tr valign="top"><td>
<bold>Sleep</bold>
<sup><bold>c</bold></sup>
<bold>:</bold>
</td><td/><td/><td/></tr><tr valign="top"><td>
<bold>Awakenings</bold>
</td><td>1-2</td><td>1</td><td>0</td></tr><tr valign="top"><td>
<bold>Sleep hours</bold>
</td><td>5</td><td>6</td><td>5</td></tr><tr valign="top"><td>
<bold>Notes</bold>
</td><td>Improved verbal communication</td><td>-</td><td>Persistent moderate nausea, daytime drowsiness</td></tr></tbody></table><table-wrap-foot><p>Legend: a) Dystonia was scored using the UDRS scale [<xref ref-type="bibr" rid="CR3">3</xref>]. Detailed scores are available in Table&#xA0;<xref rid="Tab3" ref-type="table">3</xref>. b) Self-injury was scored by counting the daily episodes of different self-injurious behaviours, following interviews with caregivers. c) Quality of sleep was scored counting the number of awakenings per night and the average hours of uninterrupted sleep, following interviews with caregivers.</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Detailed scores from patients&#x2019; UDRS scales</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Patient</bold>
</th><th>
<bold>Before ITB</bold>
</th><th>
<bold>After ITB</bold>
</th></tr></thead><tbody><tr valign="top"><td valign="middle" rowspan="3">
<bold>1</bold>
</td><td>Duration factor: 3</td><td>Duration factor: 0</td></tr><tr valign="top"><td>Motor severity factor: eyes and upper face: 1, lower face: 3, jaw and tongue: 2, larynx: 0, neck: 2, shoulder and proximal arm. 2, distal arm and hand (including elbow): 3, pelvis and proximal leg: 3, distal leg and foot (including knee): 2, trunk: 1.</td><td>Motor severity factor: eyes and upper face: 2, lower face: 1, jaw and tongue: 1, larynx: 0, neck: 1, shoulder and proximal arm 0, distal arm and hand (including elbow): 0, pelvis and proximal leg: 0, distal leg and foot (including knee): 0, trunk: 0.</td></tr><tr valign="top"><td>Total&#x2009;=&#x2009;22</td><td>Total&#x2009;=&#x2009;5</td></tr><tr valign="top"><td valign="middle" rowspan="3">
<bold>2</bold>
</td><td>Duration factor: 4</td><td>Duration factor: 0.5</td></tr><tr valign="top"><td>Motor severity factor: eyes and upper face: 1, lower face: 4, jaw and tongue: 3, larynx: 0, neck: 4, shoulder and proximal arm. 4, distal arm and hand (including elbow): 4, pelvis and proximal leg: 4, distal leg and foot (including knee): 4, trunk: 1.</td><td>Motor severity factor: eyes and upper face: 1, lower face: 0, jaw and tongue: 1, larynx: 1, neck: 1, shoulder and proximal arm. 0, distal arm and hand (including elbow): 0, pelvis and proximal leg: 1, distal leg and foot (including knee): 0, trunk: 0.</td></tr><tr valign="top"><td>Total&#x2009;=&#x2009;23</td><td>Total&#x2009;=&#x2009;6.5</td></tr><tr valign="top"><td valign="middle" rowspan="3">
<bold>3</bold>
</td><td>Duration factor: 4</td><td>Duration factor: 1</td></tr><tr valign="top"><td>Motor severity factor: eyes and upper face: 1, lower face: 4, jaw and tongue: 4, larynx: 0, neck: 3, shoulder and proximal arm. 3, distal arm and hand (including elbow): 2, pelvis and proximal leg: 3, distal leg and foot (including knee): 4, trunk: 0.</td><td>Motor severity factor: eyes and upper face: 1, lower face: 1, jaw and tongue: 2, larynx: 0, neck: 1, shoulder and proximal arm: 1, distal arm and hand (including elbow): 1, pelvis and proximal leg: 2, distal leg and foot (including knee): 1, trunk: 0.</td></tr><tr valign="top"><td>Total&#x2009;=&#x2009;38</td><td>Total&#x2009;=&#x2009;11</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec5" sec-type="discussion">
      <title>Discussion</title>
      <p>Currently, treatment approaches for LN are experimental, as therapeutic targets are not fully elucidated [<xref ref-type="bibr" rid="CR4">4</xref>,<xref ref-type="bibr" rid="CR5">5</xref>]. Dysregulation of dopaminergic pathways may be the cause of self-injurious behaviours in LN patients [<xref ref-type="bibr" rid="CR6">6</xref>] and anatomical/physiological alterations were recently demonstrated in specific brain regions [<xref ref-type="bibr" rid="CR7">7</xref>]. Impaired dopamine signalling during cerebral development could lead to the compensatory hypersensitivity of dopamine receptors, especially of the D1 subtype: this prevents the success of either dopaminergic drugs (which increase symptoms [<xref ref-type="bibr" rid="CR8">8</xref>]) and antipsychotics (which do not target D1 receptors). The dopaminergic and GABAergic systems are connected at multiple levels and GABA has a prominent influence on dopamine release in the mesolimbic and nigrostriatal circuits [<xref ref-type="bibr" rid="CR9">9</xref>]. Moreover, baclofen may serve as a functional antagonist of dopamine: GABA<sub>B</sub> receptors are coupled to G proteins that inhibit adenylyl cyclase activity, while D1 dopamine receptors activate it. Baclofen may also have a direct anxiolytic effect [<xref ref-type="bibr" rid="CR10">10</xref>] that could complement its activity on the dopaminergic balance and be useful for behavioural improvement. The use of baclofen and ITB for LN patients is not uncommon, a population study reported on ten users of oral baclofen and one of ITB, although it did not discuss therapeutic efficacy [<xref ref-type="bibr" rid="CR2">2</xref>]. Good results of ITB therapy were also previously observed in two patients, although only little information was reported [<xref ref-type="bibr" rid="CR11">11</xref>]. In order to compare available data, debate should be fostered between clinicians with different experiences on baclofen treatment in LN. Our cases further support the use of ITB in patients with LN within a multi-targeted therapy that may ameliorate both motor and behavioural symptoms. ITB may represent a viable therapy for LN patients, especially in light of the severity of this disease and of the lower comparative risk of severe side effects. Nevertheless, catheters for ITB administration may become infected, leading to removal in spite of partial ITB efficacy [<xref ref-type="bibr" rid="CR12">12</xref>]. The risks of infection may be avoided by oral administration of baclofen, which is in general safe, apart from rare cases of hepatic toxicity [<xref ref-type="bibr" rid="CR13">13</xref>]. We conclude that baclofen is potentially useful as a therapy for LN, but that additional studies should be conducted, in order to properly assess its efficacy. Both intrathecal and oral administration routes should be investigated, with systematic measurements and long follow-up periods.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-list>
          <def-item>
            <term>LN</term>
            <def>
              <p>Lesch-Nyhan syndrome</p>
            </def>
          </def-item>
          <def-item>
            <term>ITB</term>
            <def>
              <p>Intrathecal baclofen</p>
            </def>
          </def-item>
        </def-list>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>MP: research conception, manuscript preparation. LP: research conception, patient management, manuscript review. MG, FM: patient management, data collection, manuscript review. SR, EC: research conception, manuscript review. All authors read and approved the final version of the manuscript.</p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>We are thankful to dr. Valeria Padovano for language revision.</p>
      <sec id="d30e1155">
        <title>Funding sources</title>
        <p>This work was supported by Agenzia Italiana del Farmaco (AIFA) and by the Italian Ministry of Health (Ricerca Corrente 2014, to EC). The funding public institutions had no role in any part of the work.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lesch</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Nyhan</surname>
              <given-names>WL</given-names>
            </name>
          </person-group>
          <article-title>A familial disorder of uric acid metabolism and central nervous system function</article-title>
          <source>Am J Med</source>
          <year>1964</year>
          <volume>36</volume>
          <fpage>561</fpage>
          <lpage>570</lpage>
          <pub-id pub-id-type="doi">10.1016/0002-9343(64)90104-4</pub-id>
          <pub-id pub-id-type="pmid">14142409</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McCarthy</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Green</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Ogunbona</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Simmonds</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Fairbanks</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pountney</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Bryant</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>A population study of Lesch-Nyhan disease in the UK</article-title>
          <source>Dev Med Child Neurol</source>
          <year>2011</year>
          <volume>53</volume>
          <issue>1</issue>
          <fpage>34</fpage>
          <lpage>39</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1469-8749.2010.03786.x</pub-id>
          <pub-id pub-id-type="pmid">21126241</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Comella</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Leurgans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wuu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Stebbins</surname>
              <given-names>GT</given-names>
            </name>
            <name>
              <surname>Chmura</surname>
              <given-names>T</given-names>
            </name>
            <collab>Dystonia Study Group</collab>
          </person-group>
          <article-title>Rating scales for dystonia: a multicenter assessment</article-title>
          <source>Mov Disord</source>
          <year>2003</year>
          <volume>18</volume>
          <issue>3</issue>
          <fpage>303</fpage>
          <lpage>312</lpage>
          <pub-id pub-id-type="doi">10.1002/mds.10377</pub-id>
          <pub-id pub-id-type="pmid">12621634</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jankovic</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Caskey</surname>
              <given-names>TC</given-names>
            </name>
            <name>
              <surname>Stout</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Butler</surname>
              <given-names>IJ</given-names>
            </name>
          </person-group>
          <article-title>Lesch-Nyhan syndrome: a study of motor behavior and cerebrospinal fluid neurotransmitters</article-title>
          <source>Ann Neurol</source>
          <year>1988</year>
          <volume>23</volume>
          <issue>5</issue>
          <fpage>466</fpage>
          <lpage>469</lpage>
          <pub-id pub-id-type="doi">10.1002/ana.410230507</pub-id>
          <pub-id pub-id-type="pmid">2455472</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Garc&#xED;a</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Puig</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Torres</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Adenosine, dopamine and serotonin receptors imbalance in lymphocytes of Lesch-Nyhan patients</article-title>
          <source>J Inherit Metab Dis</source>
          <year>2012</year>
          <volume>35</volume>
          <issue>6</issue>
          <fpage>1129</fpage>
          <lpage>1135</lpage>
          <pub-id pub-id-type="doi">10.1007/s10545-012-9470-5</pub-id>
          <pub-id pub-id-type="pmid">22403020</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldstein</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Dopaminergic mechanisms in self-inflicting biting behavior</article-title>
          <source>Psychopharmacol Bull</source>
          <year>1989</year>
          <volume>25</volume>
          <issue>3</issue>
          <fpage>349</fpage>
          <lpage>352</lpage>
          <pub-id pub-id-type="pmid">2697008</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schretlen</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Varvaris</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Vannorsdall</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Jinnah</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
          <article-title>Regional brain volume abnormalities in Lesch-Nyhan disease and its variants: a cross-sectional study</article-title>
          <source>Lancet Neurol</source>
          <year>2013</year>
          <volume>12</volume>
          <issue>12</issue>
          <fpage>1151</fpage>
          <lpage>1158</lpage>
          <pub-id pub-id-type="doi">10.1016/S1474-4422(13)70238-2</pub-id>
          <pub-id pub-id-type="pmid">24383089</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Visser</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Schretlen</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Bloem</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Jinnah</surname>
              <given-names>HA</given-names>
            </name>
          </person-group>
          <article-title>Levodopa is not a useful treatment for Lesch-Nyhan disease</article-title>
          <source>Mov Disord</source>
          <year>2011</year>
          <volume>26</volume>
          <issue>4</issue>
          <fpage>746</fpage>
          <lpage>749</lpage>
          <pub-id pub-id-type="doi">10.1002/mds.23478</pub-id>
          <pub-id pub-id-type="pmid">21506156</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Barrot</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sesack</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Georges</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Pistis</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jhou</surname>
              <given-names>TC</given-names>
            </name>
          </person-group>
          <article-title>Braking dopamine systems: a new GABA master structure for mesolimbic and nigrostriatal functions</article-title>
          <source>J Neurosci</source>
          <year>2012</year>
          <volume>32</volume>
          <issue>41</issue>
          <fpage>14094</fpage>
          <lpage>14101</lpage>
          <pub-id pub-id-type="doi">10.1523/JNEUROSCI.3370-12.2012</pub-id>
          <pub-id pub-id-type="pmid">23055478</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Margetis</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Papageorgiou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gatzonis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Politis</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Siatouni</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sakas</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Intrathecal baclofen improves psychiatric symptoms in spasticity patients</article-title>
          <source>J Clin Psychopharmacol</source>
          <year>2014</year>
          <volume>34</volume>
          <issue>3</issue>
          <fpage>374</fpage>
          <lpage>379</lpage>
          <pub-id pub-id-type="doi">10.1097/JCP.0000000000000105</pub-id>
          <pub-id pub-id-type="pmid">24743715</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jinnah</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Visser</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Verdu</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Larovere</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ceballos-Picot</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Gonzalez-Alegre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Neychev</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Torres</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Dulac</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Desguerre</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Schretlen</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Robey</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Barabas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bloem</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Nyhan</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>De Kremer</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Eddey</surname>
              <given-names>GE</given-names>
            </name>
            <name>
              <surname>Puig</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Reich</surname>
              <given-names>SG</given-names>
            </name>
            <collab>Lesch-Nyhan Disease International Study Group</collab>
          </person-group>
          <article-title>Delineation of the motor disorder of Lesch-Nyhan disease</article-title>
          <source>Brain</source>
          <year>2006</year>
          <volume>129</volume>
          <issue>Pt 5</issue>
          <fpage>1201</fpage>
          <lpage>1217</lpage>
          <pub-id pub-id-type="doi">10.1093/brain/awl056</pub-id>
          <pub-id pub-id-type="pmid">16549399</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Deon</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Kalichman</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Booth</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Slavin</surname>
              <given-names>KV</given-names>
            </name>
            <name>
              <surname>Gaebler-Spira</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
          <article-title>Pallidal deep-brain stimulation associated with complete remission of self-injurious behaviors in a patient with Lesch-Nyhan syndrome: a case report</article-title>
          <source>J Child Neurol</source>
          <year>2012</year>
          <volume>27</volume>
          <issue>1</issue>
          <fpage>117</fpage>
          <lpage>120</lpage>
          <pub-id pub-id-type="doi">10.1177/0883073811415853</pub-id>
          <pub-id pub-id-type="pmid">21940691</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="other">Kiel LB, Hoegberg LC, Jansen T, Petersen JA, Dalhoff KP: <bold>A nationwide register-based survey of baclofen toxicity.</bold><italic>Basic Clin Pharmacol Toxicol</italic> 2014, doi:10.1111/bcpt.12344.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
